{"entity":{"id":"nct02170389","kind":"trial","name":"Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer","aka":[],"tldr":"An trial of Rocapuldencel-T run by Roswell Park Cancer Institute, terminated.","summary":"Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer is an interventional study registered as NCT02170389 by Roswell Park Cancer Institute, with 5 participants enrolled, started 2014-10-14. Conditions recorded: Recurrent Renal Cell Carcinoma, Stage I Renal Cell Cancer and Stage II Renal Cell Cancer. Interventions recorded: Laboratory Biomarker Analysis, Nephrectomy and Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02170389","url":"https://clinicaltrials.gov/study/NCT02170389"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["rocapuldencel-t"],"companies":["argos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02170389","phase":"not-applicable","setting":"Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer <pT2","sponsor":"Roswell Park Cancer Institute","enrolled":5,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02170389/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"rocapuldencel-t","kind":"drug","name":"Rocapuldencel-T","route":"/drugs/rocapuldencel-t/"}],"company":[{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/"}]}}